Our findings demonstrated that AATF inhibition exerts an anti-angiogenic effect in HCC via PEDF, and that AATF merits further investigation as a potential therapeutic target, leading to a better understanding of anti-angiogenic strategies for the treatment of HCC. This evidence concerns the gene AATF and hepatocellular carcinoma.